SEARCH NEWS & VIEWS


Preclinical Study Shows Heroin Vaccine Blocks Relapse
TSRI and Janssen Ink New Research and License Agreement
Team Finds Key to Gene-Silencing Activity
Scientists Uncover Workings of Cancer-Linked DNA-Repair Mechanism

NEWS & VIEWS HOME
PAST ISSUES
KUDOS
SCIENTIFIC CALENDAR
CA AUDITORIUM EVENTS
CONTACT




FOLLOW US
1
Preclinical Study Shows Heroin Vaccine Blocks Relapse

The TSRI team is now actively seeking a pharmaceutical company partner or other funding to sponsor clinical trials.

TSRI and Janssen Ink New Research and License Agreement

“This deal is the latest example of our corporate partnership strategy,” says Scott Forrest, TSRI’s vice president for business development.

Team Finds Key to Gene-Silencing Activity

The findings from the MacRae lab open the door to a new class of therapies.

Scientists Uncover Workings of Cancer-Linked DNA-Repair Mechanism

Work from the Wu lab shows a little-understood mechanism, although error-prone, has an overall protective role.

  • Team Finds Dissimilar Proteins Evolved Similar 7-Part Shape
  • Scientists Find Antibody that Transforms Bone Marrow Stem Cells Directly into Brain Cells
  • Scientists Help Unravel a Central Mystery of Alzheimer’s Disease
  • Team Finds Interferon, One of the Body’s Own Proteins, Induces Persistent Viral Infection
  • New Vaccine-Design Approach Targets HIV and Other Fast-Mutating Viruses
  • Scientists Identify First Potentially Effective Therapy for Human Prion Disease
  • Study Reveals How Serotonin Receptors Can Shape Drug Effects from LSD to Migraine Medication
  • Philanthropist John Moores Gives $2 Million to TSRI to Develop River Blindness Field Test
  • Hugh Rosen Makes Strides Toward New Treatments for MS, Flu and PTSD
  • Scientists Find Surprising New Influence on Cancer Genes
  • Scientists Find Promising New Approach to Preventing Progression of Breast Cancer
  • Team Finds a Key Element of Lupus, Suggesting Better Drug Targets
  • Scientists Uncover Previously Unknown Mechanism of Memory Formation
  • Andrew Su Sets Out to Scale Mountains of Data